Citigroup maintains Buy rating for ResMed, raises PT to $345 from $330.

lunes, 2 de febrero de 2026, 2:46 pm ET1 min de lectura
C--
RMD--

Citigroup maintains Buy rating for ResMed, raises PT to $345 from $330.

Citigroup maintains Buy rating for ResMed, raises PT to $345 from $330.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios